Cargando…
Radionuclide Delivery Strategies in Tumor Treatment: A Systematic Review
The aim of this review was to assess recent progress in targeted radionuclide tumor therapy, focusing on the best delivery strategies. A literature search was conducted in PubMed, Web of Science, and Scopus using the terms “radionuclides”, “liposomes”, “avidin–biotin interaction”, “theranostic”, and...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9332578/ https://www.ncbi.nlm.nih.gov/pubmed/35892711 http://dx.doi.org/10.3390/cimb44080225 |
_version_ | 1784758682501775360 |
---|---|
author | Poletto, Giulia Cecchin, Diego Bartoletti, Paola Venturini, Francesca Realdon, Nicola Evangelista, Laura |
author_facet | Poletto, Giulia Cecchin, Diego Bartoletti, Paola Venturini, Francesca Realdon, Nicola Evangelista, Laura |
author_sort | Poletto, Giulia |
collection | PubMed |
description | The aim of this review was to assess recent progress in targeted radionuclide tumor therapy, focusing on the best delivery strategies. A literature search was conducted in PubMed, Web of Science, and Scopus using the terms “radionuclides”, “liposomes”, “avidin–biotin interaction”, “theranostic”, and “molecular docking”. The 10 year filter was applied, except for the avidin–biotin interaction. Data were retrieved from both preclinical and clinical settings. Three targeting strategies were considered: pretargeting, liposomes, and ligands. Pretargeting can be achieved by exploiting the avidin–biotin interaction. This strategy seems very promising, although it has been investigated mainly in resectable tumors. Radiolabeled liposomes have attracted new interest as probes to identify the most suitable patients for treatment with liposomal formulations of common chemotherapeutics. The use of ligands for the delivery of radiotherapeutics to a specific target is still the most appealing strategy for treating tumors. The most appropriate ligand can be identified by virtually simulating its interaction with the receptor. All strategies showed great potential for use in targeted radionuclide therapy, but they also have numerous drawbacks. The most promising option is probably the one based on the use of new ligands. |
format | Online Article Text |
id | pubmed-9332578 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-93325782022-07-29 Radionuclide Delivery Strategies in Tumor Treatment: A Systematic Review Poletto, Giulia Cecchin, Diego Bartoletti, Paola Venturini, Francesca Realdon, Nicola Evangelista, Laura Curr Issues Mol Biol Review The aim of this review was to assess recent progress in targeted radionuclide tumor therapy, focusing on the best delivery strategies. A literature search was conducted in PubMed, Web of Science, and Scopus using the terms “radionuclides”, “liposomes”, “avidin–biotin interaction”, “theranostic”, and “molecular docking”. The 10 year filter was applied, except for the avidin–biotin interaction. Data were retrieved from both preclinical and clinical settings. Three targeting strategies were considered: pretargeting, liposomes, and ligands. Pretargeting can be achieved by exploiting the avidin–biotin interaction. This strategy seems very promising, although it has been investigated mainly in resectable tumors. Radiolabeled liposomes have attracted new interest as probes to identify the most suitable patients for treatment with liposomal formulations of common chemotherapeutics. The use of ligands for the delivery of radiotherapeutics to a specific target is still the most appealing strategy for treating tumors. The most appropriate ligand can be identified by virtually simulating its interaction with the receptor. All strategies showed great potential for use in targeted radionuclide therapy, but they also have numerous drawbacks. The most promising option is probably the one based on the use of new ligands. MDPI 2022-07-22 /pmc/articles/PMC9332578/ /pubmed/35892711 http://dx.doi.org/10.3390/cimb44080225 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Poletto, Giulia Cecchin, Diego Bartoletti, Paola Venturini, Francesca Realdon, Nicola Evangelista, Laura Radionuclide Delivery Strategies in Tumor Treatment: A Systematic Review |
title | Radionuclide Delivery Strategies in Tumor Treatment: A Systematic Review |
title_full | Radionuclide Delivery Strategies in Tumor Treatment: A Systematic Review |
title_fullStr | Radionuclide Delivery Strategies in Tumor Treatment: A Systematic Review |
title_full_unstemmed | Radionuclide Delivery Strategies in Tumor Treatment: A Systematic Review |
title_short | Radionuclide Delivery Strategies in Tumor Treatment: A Systematic Review |
title_sort | radionuclide delivery strategies in tumor treatment: a systematic review |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9332578/ https://www.ncbi.nlm.nih.gov/pubmed/35892711 http://dx.doi.org/10.3390/cimb44080225 |
work_keys_str_mv | AT polettogiulia radionuclidedeliverystrategiesintumortreatmentasystematicreview AT cecchindiego radionuclidedeliverystrategiesintumortreatmentasystematicreview AT bartolettipaola radionuclidedeliverystrategiesintumortreatmentasystematicreview AT venturinifrancesca radionuclidedeliverystrategiesintumortreatmentasystematicreview AT realdonnicola radionuclidedeliverystrategiesintumortreatmentasystematicreview AT evangelistalaura radionuclidedeliverystrategiesintumortreatmentasystematicreview |